Scott B - Search Results

1

Tumor antigens are constitutively presented in the draining lymph nodes.

Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BW, Scott B. Marzo AL, et al. Among authors: scott b. J Immunol. 1999 May 15;162(10):5838-45. J Immunol. 1999. PMID: 10229818

2

Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.

Robinson BW, Lake RA, Nelson DJ, Scott BA, Marzo AL. Robinson BW, et al. Among authors: scott ba. Immunol Cell Biol. 1999 Dec;77(6):552-8. doi: 10.1046/j.1440-1711.1999.00876.x. Immunol Cell Biol. 1999. PMID: 10571677 Review.

3

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.

Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW. Nowak AK, et al. Among authors: scott b. J Immunol. 2003 May 15;170(10):4905-13. doi: 10.4049/jimmunol.170.10.4905. J Immunol. 2003. PMID: 12734333

4

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.

Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B. Marzo AL, et al. Among authors: scott b. J Immunol. 2000 Dec 1;165(11):6047-55. doi: 10.4049/jimmunol.165.11.6047. J Immunol. 2000. PMID: 11086036

5

T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.

Marzo AL, Lake RA, Robinson BW, Scott B. Marzo AL, et al. Among authors: scott b. Cancer Res. 1999 Mar 1;59(5):1071-9. Cancer Res. 1999. PMID: 10070965

6

CD8(+) T cell-mediated spontaneous diabetes in neonatal mice.

Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, Lo D, Sherman LA. Morgan DJ, et al. Among authors: scott b. J Immunol. 1996 Aug 1;157(3):978-83. J Immunol. 1996. PMID: 8757600

7

Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.

Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BW, Scott B. Caminschi I, et al. Among authors: scott b. Am J Respir Cell Mol Biol. 1999 Sep;21(3):347-56. doi: 10.1165/ajrcmb.21.3.3575. Am J Respir Cell Mol Biol. 1999. PMID: 10460752

8

Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.

Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, Lake RA. Robinson C, et al. Among authors: scott b. Am J Respir Cell Mol Biol. 2000 May;22(5):550-6. doi: 10.1165/ajrcmb.22.5.3930. Am J Respir Cell Mol Biol. 2000. PMID: 10783126

9

Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.

Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Marzo AL, et al. Among authors: scott b. Cancer Res. 1997 Aug 1;57(15):3200-7. Cancer Res. 1997. PMID: 9242450

10

Interleukin-12 induces an effective antitumor response in malignant mesothelioma.

Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BW. Caminschi I, et al. Among authors: scott b. Am J Respir Cell Mol Biol. 1998 Nov;19(5):738-46. doi: 10.1165/ajrcmb.19.5.3257m. Am J Respir Cell Mol Biol. 1998. PMID: 9806738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,290 results

Search Page

Filters